Inactivation of Sp1 by genetic and pharmacological approaches abrogated BCR/ABL expression, leading to suppression of BCR/ABL kinase signaling and CML cell proliferation. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.